ResultsIQ

ResultsIQ › Latest results › Zydus Wellness Limited

Zydus Wellness Limited Q4 FY25 results deck summary

NSE: ZYDUSWELL · BSE: 531335

Results deck of 19 May 2025, summarised by AI from the filing.

Q4 FY25 net sales ₹9,106 mn (+17.0% YoY), EBITDA ₹1,900 mn (+17.1%), PAT ₹1,719 mn (+14.4%); targeting 8-10% international revenue in 4-5 years.

Key takeaways

  1. Q4 FY25 results Net sales ₹9,106 mn (Q4 FY24: ₹7,780 mn, +17.0%), EBITDA ₹1,900 mn (+17.1%), PAT ₹1,719 mn (+14.4%).
  2. International target Targeting 8-10% of revenues from international business in next 4 to 5 years.
  3. Naturell acquisition Completed acquisition of 100% equity share capital of Naturell (India) Private Limited in the previous quarter; integration progressing smoothly.
  4. Brand growth Glucon-D contributed 69% and Nycil 51% to increase in category penetration.

Original filing on BSE

Zydus Wellness Limited Q1 FY27 results

As filed: Revenue ₹1,437 cr (+67% year on year), EBITDA ₹242 cr (+55% year on year), PAT ₹119 cr (−7% year on year), EBITDA margin 16.8% (−130 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,485 cr (+63% year on year), EBITDA ₹270 cr (+43% year on year), PAT ₹162 cr (−6% year on year), EBITDA margin 18.2% (−251 bps). Score 58 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 251 bps year on year. Tax rate 9%. Consolidated profit -6% but standalone +166%. Revenue rose ₹572 cr on a year ago, more than the ₹130 cr it added the year before. Share price after the results: +0.8% in 30 days (Nifty 500: +2.6%).
  • Q3 FY26: Revenue ₹965 cr (+109% year on year), EBITDA ₹61.0 cr (+300% year on year), PAT −₹39.9 cr (−300% year on year), EBITDA margin 6.3% (+329 bps). Score 20 of 100, Below trend. Revenue and EBITDA growth were well above the company's own trend; profit before exceptional items growth was well below it. EBITDA margin rose 329 bps year on year. Consolidated profit -765% but standalone +1%. Share price after the results: −12.0% in 30 days (Nifty 500: −0.6%).
  • Q2 FY26: Revenue ₹651 cr (+32% year on year), EBITDA ₹23.0 cr (+15% year on year), PAT −₹53.0 cr (−194% year on year), EBITDA margin 3.5% (−52 bps). Score 20 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit before exceptional items growth was well below it. EBITDA margin fell 52 bps year on year. Consolidated profit -352% but standalone +0%. Revenue fell 24% from last quarter. Share price after the results: −11.5% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹861 cr (+2% year on year), EBITDA ₹156 cr (0% year on year), PAT ₹128 cr (−14% year on year), EBITDA margin 18.1% (−43 bps). Score 28 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin fell 43 bps year on year. Tax rate 12%. Consolidated profit -14% but standalone +17%. Revenue fell 6% from last quarter. Share price after the results: +0.3% in 30 days (Nifty 500: −2.4%).
  • Q4 FY25: Revenue ₹913 cr (+17% year on year), EBITDA ₹189 cr (+17% year on year), PAT ₹172 cr (+15% year on year), EBITDA margin 20.7% (+1 bps). Score 61 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin was flat year on year. Tax rate 1%. Consolidated profit +15% but standalone -29%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +7.2% in 30 days (Nifty 500: +2.4%).
  • Q3 FY25: Revenue ₹462 cr (+15% year on year), EBITDA ₹14.0 cr (+8% year on year), PAT ₹6.0 cr, EBITDA margin 3.0% (−20 bps). Score 46 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 20 bps year on year. Other income 40% of PBT. Tax rate 40%. Revenue fell 6% from last quarter.
  • Q2 FY25: Revenue ₹493 cr (+12% year on year), EBITDA ₹20.0 cr (+11% year on year), PAT ₹21.0 cr (+100% year on year), EBITDA margin 4.1% (−3 bps). Score 55 of 100, In line with trend. EBITDA margin was flat year on year. Tax rate 13%. Consolidated profit +250% but standalone +0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 41% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Zydus Wellness Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.